Hyperbaric oxygen therapy for hemorrhagic radiation cystitis.

Hemorrhagic radiation cystitis remains a challenging complication following pelvic radiation therapy. While some patients respond to conservative measures, many experience persistent or severe hematuria. Prior research has shown limited success with standard treatments, leaving a gap in effective management strategies. This uncertainty drove the need for alternative therapies like hyperbaric oxygen. No prior work had resolved the long-term efficacy or safety of HBO in this context. Established knowledge includes the role of oxygen in tissue repair, but its application in radiation-induced bladder damage was unclear. The need for durable solutions led to this investigation. Patients with severe hematuria often require invasive interventions, highlighting the urgency for non-surgical options.

This study aimed to evaluate hyperbaric oxygen therapy as a treatment for hemorrhagic radiation cystitis. The specific problem addressed was persistent hematuria in patients with ASTRO grades 3-4. The motivation stemmed from the lack of durable, non-invasive solutions for this condition. Researchers proposed HBO as a potential intervention based on its known effects on wound healing. The goal was to assess both efficacy and safety in a clinical setting. The study focused on patients who had already undergone pelvic radiation therapy. The authors sought to determine whether HBO could control bleeding and reduce the need for surgical interventions. The primary outcome was resolution of hematuria following HBO sessions.

The study involved 32 patients with ASTRO grades 3-4 hematuria due to radiation cystitis. Participants received daily 90-minute HBO sessions at 2 ATM with 100% oxygen. The median number of sessions was 30, ranging from 3 to 53. The median age of participants was 72.5 years, with a range from 48 to 88. The time between radiation therapy and HBO initiation was 4 years on average. Hematuria resolution was the primary outcome measured. Secondary outcomes included complications and the need for surgical interventions. Researchers tracked follow-up periods ranging from 5 to 74 months.

Hematuria resolved in 27 out of 32 patients (84%). Five patients had persistent hematuria despite HBO treatment. Cystectomy was required in two cases, and other procedures were performed in three patients. At median follow-up of 12 months, 16 patients remained free of hematuria. Ten patients experienced mild recurrence requiring no further treatment. One patient with ASTRO grade 4 hematuria needed bladder irrigation and blood transfusions. Complications included eardrum perforation in four patients and transient vertigo in one. No HBO sessions were discontinued due to adverse effects.

The authors concluded that HBO therapy is effective in controlling bleeding in 84% of patients with HRC. A durable freedom from significant hematuria was achieved in 96% of cases. The treatment was generally safe, with no discontinuations due to complications. The findings suggest HBO as a viable option for managing severe radiation cystitis. The study supports further exploration of HBO in this clinical setting. Researchers emphasized the need for long-term follow-up to confirm durability. The results align with prior expectations about HBO's role in tissue repair. The authors did not propose HBO as a first-line treatment but as a valuable alternative.